JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Animal models
Acute kidney injury in male Wistar rat models
Dosage form
10 mg/kg(p.o.)
Application
After cisplatin administration, rats were orally administered cefdinir on day 6. It was observed that cefdinir significantly increased plasma exposure compared to the control group. At the same time, cumulative urinary excretion was significantly reduced in the cisplatin-induced AKI group. It could be estimated that morbid condition could significantly affect cefdinir's release in vivo. These results indicated that under the conditions of cisplatin-induced AKI, the pharmacokinetics of cefdinir changed significantly.
Other notes
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.
References:
[1]. Wang H, Sun P, Wang C, Meng Q, Liu Z, Huo X, Sun H, Ma X, Peng J, Liu K. Pharmacokinetic changes of cefdinir and cefditoren and its molecular mechanisms in acute kidney injury in rats. J Pharm Pharmacol. 2018 Nov;70(11):1503-1512. doi: 10.1111/jphp.12994. Epub 2018 Jul 25. PMID: 30047127.